Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have been given a consensus recommendation of "Buy" by the nine research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $218.63.
KRYS has been the subject of several recent research reports. Chardan Capital reissued a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research report on Wednesday. Guggenheim reduced their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday. HC Wainwright restated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective on the stock. Finally, Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th.
View Our Latest Research Report on Krystal Biotech
Insider Buying and Selling
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at $2,208,472.88. The trade was a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.
Institutional Investors Weigh In On Krystal Biotech
A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC raised its holdings in shares of Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after buying an additional 21,133 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after buying an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after buying an additional 6,600 shares during the last quarter. Hood River Capital Management LLC raised its holdings in shares of Krystal Biotech by 2.1% in the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after buying an additional 10,622 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Krystal Biotech by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after buying an additional 71,200 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.
Krystal Biotech Stock Down 3.6%
KRYS stock traded down $4.94 during midday trading on Tuesday, hitting $132.23. The company's stock had a trading volume of 329,798 shares, compared to its average volume of 300,407. Krystal Biotech has a 52-week low of $131.71 and a 52-week high of $219.34. The firm has a market capitalization of $3.82 billion, a P/E ratio of 44.22 and a beta of 0.79. The firm has a 50-day simple moving average of $171.56 and a 200-day simple moving average of $170.01.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. On average, sell-side analysts expect that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.
Krystal Biotech Company Profile
(
Get Free ReportKrystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Recommended Stories

Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.